TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25330984

Group type: EXPERIMENTAL
Intervention: Spectra Optia apheresis system (SO) for red blood cell exchange (RBCX) procedures
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Spectra Optia apheresis system (SO) for achieving desired final hematocrit (Hct)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Spectra Optia apheresis system (SO) regarding safety
Number of subjects: 72
Study: 25331113

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m² plus liposomal doxorubicin 20 mg/m² (R-Dox) every 3 weeks
Number of subjects: 17
Study: 25331535

Group type: EXPERIMENTAL
Intervention: Fractional exhaled nitric oxide (FeNO)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Immune globulin E (IgE)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Peripheral blood eosinophils
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 131
Study: 25331616

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2, intravenous, twice a week for 2 weeks, maximum of 8 cycles)
Number of subjects: 517
Study: 25332322

Group type: EXPERIMENTAL
Intervention: Neck adipose tissue (NAT) compartments measurement
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: NAT compartments in women
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: NAT compartments in men
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Comparison of NAT across lean, overweight, and obese groups
Number of subjects: 303
Study: 25332326

Group type: EXPERIMENTAL
Intervention: [(13)C5]5-formyltetrahydrofolate delivered in a pH-sensitive enteric caplet (855 nmol / 400 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous injection of [(13)C5]5-formyltetrahydrofolate (214 nmol)
Number of subjects: 0
Study: 25332483

Group type: EXPERIMENTAL
Intervention: 54 g/d LNS with milk protein base (milk-LNS)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: 54 g/d LNS with soy protein base (soy-LNS)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: 71 g/d corn-soy blend (CSB)
Number of subjects: 840

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: milk-LNS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: soy-LNS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: CSB
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: All groups (milk-LNS, soy-LNS, CSB, Control)
Number of subjects: 840
Study: 25333474

Group type: EXPERIMENTAL
Intervention: T2-weighted STIR
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACUT2E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EGE
Number of subjects: 40
Study: 25334031

Group type: EXPERIMENTAL
Intervention: ClinicalTrials.gov registry
Number of subjects: 437

Group type: COMPARATOR
Intervention: Contacting trial coordinators
Number of subjects: 437
Study: 25335783

Group type: EXPERIMENTAL
Intervention: pMTCT cascade analysis tool
Number of subjects: 32
Study: 25335932

Group type: EXPERIMENTAL
Intervention: OSI-906 50 mg BID; everolimus 5 mg QD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OSI-906 100 mg BID; everolimus 10 mg QD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OSI-906 100 mg BID; everolimus 5 mg QD
Number of subjects: 18
Study: 25336464

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg IV infusion at baseline and on day 15)
Number of subjects: 20
Study: 25336940

Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 6MWD
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Indirect effect of FEV1 on 6MWD through IL-6
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Age as a moderator
Number of subjects: 153
Study: 25338281

Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2 imaging
Number of subjects: 44

Group type: COMPARATOR
Intervention: 99mTc-MDP bone scan
Number of subjects: 44
Study: 25338318

Group type: EXPERIMENTAL
Intervention: Nintedanib (oral, small-molecule tyrosine kinase inhibitor)
Number of subjects: 36
Study: 25338926

Group type: EXPERIMENTAL
Intervention: FPG ≥5.6 mmol/L
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: A1C ≥ 5.7% (39 mmol/mol)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: FPG combined with A1C (FPG ≥5.6 mmol/L and/or A1C ≥5.7% [39 mmol/mol])
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: A1C combined with FPG
Number of subjects: 216
Study: 25340593

Group type: EXPERIMENTAL
Intervention: poly-L-lactic acid
Number of subjects: 15
Study: 25340778

Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy (cART) for 8 months
Number of subjects: 9
Study: 25340784

Group type: EXPERIMENTAL
Intervention: GLP-1 agonist therapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HbA1c achieved
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HbA1c change
Number of subjects: 230
Study: 25340854

Group type: EXPERIMENTAL
Intervention: Persistence or development of new ECG LVH
Number of subjects: 725

Group type: COMPARATOR
Intervention: Regression or continued absence of ECG LVH
Number of subjects: 725
Study: 25341454

Group type: EXPERIMENTAL
Intervention: CVD risk algorithms developed using competing risks survival analysis.
Number of subjects: 77251

Group type: EXPERIMENTAL
Intervention: Linkage to administrative healthcare databases for incident CVD outcomes assessment.
Number of subjects: 77251
Study: 25341556

Group type: EXPERIMENTAL
Intervention: Emphysema-predominant COPD
Number of subjects: 4197

Group type: EXPERIMENTAL
Intervention: Non-emphysematous COPD
Number of subjects: 4197
Study: 25341628

Group type: EXPERIMENTAL
Intervention: New percentile charts for birth weight, length, and head circumference
Number of subjects: 863

Group type: COMPARATOR
Intervention: Comparison of new birth weight curves with data from Finland
Number of subjects: 863
Study: 25341798

Group type: EXPERIMENTAL
Intervention: T-cell profiles in adipose tissue (specifically CD4 and CD8 T cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th1 frequency in SAT and VAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th2 frequency in VAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th2 in both depots and peripheral blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th1 in SAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipose tissue expression of interleukin-10
Number of subjects: 0
Study: 25342141

Group type: EXPERIMENTAL
Intervention: MEDI-573 (5 mg/kg, 15 mg/kg, 45 mg/kg on Day 1, 8, and 15 of 21-day cycles)
Number of subjects: 10
Study: 25343737

Group type: EXPERIMENTAL
Intervention: Interview survey tool about bullying administered to children
Number of subjects: 50
Study: 25344223

Group type: EXPERIMENTAL
Intervention: Tactile imaging (TI)
Number of subjects: 22
Study: 25344362

Group type: EXPERIMENTAL
Intervention: Trametinib and everolimus (daily dosing with both agents)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Trametinib and everolimus (daily dosing with trametinib and intermittent everolimus dosing)
Number of subjects: 67
Study: 25344427

Group type: EXPERIMENTAL
Intervention: Case review process for eligibility determination
Number of subjects: 697
Study: 25344522

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization analyses using extended probe panels applied to CD34(+) peripheral blood cells
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Complete International Prognostic Scoring System assessment including cytogenetic data from fluorescence in situ hybridization analyses
Number of subjects: 328

Group type: COMPARATOR
Intervention: Chromosome banding results from 2902 previously published patients with MDS
Number of subjects: 328
Study: 25344536

Group type: EXPERIMENTAL
Intervention: Clostridium OTU overabundance in prediagnosis samples from infants with established NEC
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Klebsiella OTU overabundance in prediagnosis samples from NEC infants not carrying profuse C. perfringens
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Prolonged continuous positive airway pressure (CPAP) therapy with supplemental oxygen
Number of subjects: 369
Study: 25344620

Group type: EXPERIMENTAL
Intervention: Virtual world intervention (Second Life)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Face-to-face intervention
Number of subjects: 89
Study: 25345578

Group type: EXPERIMENTAL
Intervention: ROX coupler implantation in ovine aortas for up to 12 months
Number of subjects: 0
Study: 25345697

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 103

Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 103
Study: 25347448

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Oral anti-psychotic therapy (retrospective)
Number of subjects: 433
Study: 25348273

Group type: EXPERIMENTAL
Intervention: Successful early percutaneous revascularization in derivation cohort
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Successful early percutaneous revascularization in validation cohort
Number of subjects: 521
Study: 25348520

Group type: EXPERIMENTAL
Intervention: Faldaprevir (480 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal renal function (Control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Renal impairment (Experimental)
Number of subjects: 32
Study: 25348609

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg elemental zinc, oral zinc acetate, twice daily for 14 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (RR homozygotes)
Number of subjects: 55
Study: 25349073

Group type: EXPERIMENTAL
Intervention: Tumor pathologic variables alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: tHb combined with tumor pathological variables
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: oxyHb combined with tumor variables
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: tHb or oxyHb added to tumor pathologic variables
Number of subjects: 34
Study: 25349290

Group type: EXPERIMENTAL
Intervention: HA-WBRT (Hippocampal Avoidance Whole-Brain Radiotherapy) to 30 Gy in 10 fractions
Number of subjects: 113

Group type: COMPARATOR
Intervention: Historical control (WBRT without hippocampal avoidance)
Number of subjects: 113
Study: 25349960

Group type: EXPERIMENTAL
Intervention: Women aged 50 to 54 years without baseline osteoporosis
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: Women aged 60 to 64 years without baseline osteoporosis
Number of subjects: 4068

Group type: EXPERIMENTAL
Intervention: All women aged 50 to 64 years with baseline osteoporosis
Number of subjects: 4068

Group type: COMPARATOR
Intervention: Women aged 50 to 64 years without osteoporosis on their first BMD test
Number of subjects: 4068
Study: 25349968

Group type: EXPERIMENTAL
Intervention: Pazopanib (oral angiogenesis inhibitor targeting VEGFR/PDGFR/c-Kit)
Number of subjects: 0
Study: 25350762

Group type: EXPERIMENTAL
Intervention: Thrombolysis (iv-tPA), n=62
Number of subjects: 164

Group type: COMPARATOR
Intervention: No thrombolysis (Control), n=102
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Thrombolysis (iv-tPA)
Number of subjects: 164
Study: 25350980

Group type: EXPERIMENTAL
Intervention: Low-saturated fat dietary counseling
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Sex (boys vs girls)
Number of subjects: 395
Study: 25351198

Group type: EXPERIMENTAL
Intervention: IK-5001 (2 ml of 1% sodium alginate plus 0.3% calcium gluconate) administered by selective injection through the infarct-related coronary artery within 7 days after myocardial infarction
Number of subjects: 27
Study: 25352936

Group type: EXPERIMENTAL
Intervention: Efavirenz monotherapy (600 mg single dose and 600 mg/d for 17 days)
Number of subjects: 60
Study: 25353072

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention (M6) with a 3-week residential program (D21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 42
Study: 25353277

Group type: EXPERIMENTAL
Intervention: Exposed group (neonatal hyperbilirubinaemia)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Unexposed group (age-, sex-, and gestational age-matched)
Number of subjects: 167
Study: 25354824

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery
Number of subjects: 0
Study: 25354827

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) procedure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI and contrast-enhanced ultrasound of the prostate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole mount histopathological examination
Number of subjects: 16
Study: 25355245

Group type: EXPERIMENTAL
Intervention: Oral lenalidomide at a dose of 25 mg daily on days 1 to 21 of each 28-day cycle
Number of subjects: 39
Study: 25355284

Group type: EXPERIMENTAL
Intervention: 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24
Number of subjects: 91
Study: 25355590

Group type: EXPERIMENTAL
Intervention: AMH test for high response prediction
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: AMH test for low response prediction
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: AMH test with specificity of ∼90% for high response
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: AMH test with specificity of ∼90% for low response
Number of subjects: 487

Group type: COMPARATOR
Intervention: Comparison of ongoing pregnancy rates among groups
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: AMH vs. female age and BMI for prediction accuracy
Number of subjects: 487
Study: 25355699

Group type: EXPERIMENTAL
Intervention: (124)I-cRGDY-PEG-C dot particles
Number of subjects: 0
Study: 25355716

Group type: EXPERIMENTAL
Intervention: High SPARC expression (IRS ≥6)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Low SPARC expression (IRS <6)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: High SPARC expression in triple-negative tumors
Number of subjects: 667

Group type: COMPARATOR
Intervention: Low SPARC expression in triple-negative tumors
Number of subjects: 667
Study: 25355775

Group type: EXPERIMENTAL
Intervention: Root canal therapy (RCT)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Baseline factors predicting severe postoperative pain
Number of subjects: 708
Study: 25355819

Group type: EXPERIMENTAL
Intervention: Ibrutinib (280 or 560 mg) combined with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2))
Number of subjects: 48
Study: 25355844

Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Optimal plasma concentration of efavirenz
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Suboptimal plasma concentration of efavirenz
Number of subjects: 53
Study: 25356881

Group type: EXPERIMENTAL
Intervention: COPD exacerbations requiring hospital admission
Number of subjects: 2138

Group type: EXPERIMENTAL
Intervention: Prior history of exacerbation requiring hospital admission
Number of subjects: 2138

Group type: EXPERIMENTAL
Intervention: Hospitalization for exacerbation
Number of subjects: 2138
Study: 25357008

Group type: EXPERIMENTAL
Intervention: Behavioral intervention via Facebook
Number of subjects: 21

Group type: COMPARATOR
Intervention: Informational control via Facebook
Number of subjects: 21
Study: 25357043

Group type: EXPERIMENTAL
Intervention: AeroForm patient-controlled tissue expanders; 10-cc dose of carbon dioxide gas administered three times daily with a 3-hour lockout until full expansion achieved.
Number of subjects: 33

Group type: COMPARATOR
Intervention: AeroForm breast tissue expander
Number of subjects: 33
Study: 25358735

Group type: EXPERIMENTAL
Intervention: Dynamic structure-function (DSF) model
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ordinary least squares linear regression (OLSLR)
Number of subjects: 220
Study: 25358826

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase type 5 inhibitors (PDE5i)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weekly use of PDE5i
Number of subjects: 64
Study: 25358868

Group type: EXPERIMENTAL
Intervention: Chronic abdominal pain (CAP) group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Participants with poor sleep quality
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Participants with CAP
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: BDNF genotype interaction
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Down-regulation of specific genes (IGF1, SPATS2L, IGHG1)
Number of subjects: 59
Study: 25359291

Group type: EXPERIMENTAL
Intervention: Methotrexate and adalimumab treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Adalimumab treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Baseline sOX40L levels
Number of subjects: 39

Group type: COMPARATOR
Intervention: sOX40/sOX40L ratio
Number of subjects: 39
Study: 25359432

Group type: EXPERIMENTAL
Intervention: Minor allele of rs1205 C > T genotype (TT)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Common H2 haplotype characterized by the T allele of rs1205
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: SNPs and haplotypes
Number of subjects: 315
Study: 25359642

Group type: EXPERIMENTAL
Intervention: Monitoring (oral hygiene instruction, applying or prescribing fluoride or varnish, or both)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Invasive therapy
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Young patient age (< 18 years)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Lesion on a molar
Number of subjects: 1341
Study: 25359677

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25359988

Group type: EXPERIMENTAL
Intervention: Rituximab and chemotherapy (6 5-day cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy; Rituximab given before each cycle and twice as maintenance, total of 8 doses)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Rituximab and chemotherapy
Number of subjects: 363
Study: 25359994

Group type: EXPERIMENTAL
Intervention: Cytokine pathway treatment targeting STAT3
Number of subjects: 13
Study: 25360300

Group type: EXPERIMENTAL
Intervention: GORD diagnosed based on reflux oesophagitis, pathological oesophageal acid exposure, and/or positive symptom-acid association probability.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Physician interviews using a prespecified symptom checklist.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Reflux Disease Questionnaire (RDQ).
Number of subjects: 336
Study: 25360888

Group type: EXPERIMENTAL
Intervention: A-allele of the rs12041331 SNP in the PEAR1 gene
Number of subjects: 985

Group type: COMPARATOR
Intervention: Other SNPs analyzed
Number of subjects: 985

Group type: COMPARATOR
Intervention: 14 SNPs previously suggested to influence aspirin efficacy
Number of subjects: 985
Study: 25361564

Group type: EXPERIMENTAL
Intervention: TAo-TAVI using the Edwards SAPIEN Valve
Number of subjects: 300
Study: 25361625

Group type: EXPERIMENTAL
Intervention: Thalidomide (starting dose 200 mg/day, escalated to a maximum of 1,000 mg/day) combined with TACE
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thalidomide and TACE
Number of subjects: 56
Study: 25361643

Group type: EXPERIMENTAL
Intervention: GDm-health system (smartphone-based blood glucose monitoring)
Number of subjects: 52
Study: 25361834

Group type: EXPERIMENTAL
Intervention: T2DM group
Number of subjects: 796

Group type: COMPARATOR
Intervention: Non-T2DM group
Number of subjects: 796
Study: 25361837

Group type: EXPERIMENTAL
Intervention: Individualised DAPT guided by MEA (treatment for HPR to ADP with prasugrel or ticagrelor, clopidogrel reloading)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Individualised DAPT guided by MEA
Number of subjects: 1008
Study: 25361987

Group type: EXPERIMENTAL
Intervention: (90)Y-Ibritumomab tiuxetan in association with a fludarabine-based reduced-intensity conditioning (RIC) regimen
Number of subjects: 31
Study: 25361995

Group type: EXPERIMENTAL
Intervention: Young adults (18-29 years old)
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Adults (30-59 years old)
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Elderly patients (at least 60 years old)
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors-treated young adults (18-29 years old)
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors-treated adults (30-59 years old)
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors-treated elderly patients (at least 60 years old)
Number of subjects: 2784
Study: 25362970

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until progression or unacceptable toxicities
Number of subjects: 34
Study: 25363015

Group type: EXPERIMENTAL
Intervention: 2D and 3D ultrasound estimations of uterine volume
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 3D observations of uterine volume
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Resistance index (RI) of the uterine artery
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RI of the arcuate artery
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Uterine involution
Number of subjects: 81
Study: 25363329

Group type: EXPERIMENTAL
Intervention: TB-DM (Type 2 diabetes mellitus with pulmonary tuberculosis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TB-NDM (No diabetes with pulmonary tuberculosis)
Number of subjects: 0
Study: 25363606

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg once daily for 4 weeks
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg added to tamsulosin after 4 weeks for patients with residual symptoms
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Predictive factors for solifenacin add-on therapy
Number of subjects: 254
Study: 25363997

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT) of warfarin, aspirin, and clopidogrel
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Dual therapy (DT) of warfarin and single antiplatelet agent (aspirin or clopidogrel)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT) of aspirin and clopidogrel
Number of subjects: 401
Study: 25364884

Group type: EXPERIMENTAL
Intervention: sofosbuvir plus ledipasvir for 12 weeks
Number of subjects: 14
Study: 25366641

Group type: EXPERIMENTAL
Intervention: Delayed cerebral infarction (DCI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No delayed cerebral infarction (Control)
Number of subjects: 120